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Background: Immunosuppressive (IS) therapy is indicated to treat progressive sarcoidosis, but
randomized controlled trials to guide physicians in the use of steroid sparing agents are lack-
ing. The aim of this retrospective study was to examine the role of mycophenolate mofetil
(MMF) as an alternative therapy in the treatment of sarcoidosis.
Methods: A retrospective chart review of all patients who had been prescribed MMF between
January 2008 and October 2011 was conducted. Patients with insufficient data or who had
another IS therapy initiated concomitantly with MMF, including prednisone, were excluded.
Physiological data obtained at the time MMF therapy was initiated as well as six and twelve
months before and after therapy was extracted. Longitudinal analyses of the effect of MMF
on changes in pulmonary function at MMF start, 6 months, 12 months pre and post MMF therapy
were conducted.
Results: 37/76 patients met our inclusion/exclusion criteria. There were no statistically signif-
icant changes in PFT measurements pre and post MMF therapy. We did find a trend (pZ 0.07)
towards improvement in DLCO 12 months pre and post MMF in patients who were started on
MMF due to intolerance to previous IS therapy compared to those who were unresponsive to
their previous IS therapy. We also noted a reduction in prednisone dose in those treated with
MMF.
Conclusion: MMF appears to offer no extra benefit to sarcoidosis patients unresponsive to pre-
vious steroid-sparing agents, but may be beneficial in patients intolerant to their previouswish Health, Division of Environmental and Occupational Health Sciences, 1400 Jackson St, G204,
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MMF mycophenolate mofet
NJH National Jewish Healt
ATS American Thoracic Soc
ERS European Respiratory
IS immunosuppressive th
PFT pulmonary function te
FEV1 forced expiratory volu
FVC forced vital capacitysteroid-sparing agent. Additional studies investigating the efficacy of MMF as the initial steroid-
sparing agent are needed to further clarify the role of MMF in sarcoidosis.






me in the first second
FEV1/FVC ratio of forced expiratory volume in the first
second to forced vital capacity
TLC total lung capacity
DLCO diffusion capacity for carbon monoxide
DLCO/VA diffusion capacity for carbon monoxide
adjusted for alveolar volume
LMM linear mixed models
CS corticosteroidsIntroduction
Sarcoidosis is a multi-system granulomatous disorder with
lung involvement in over 90% of cases [1]. Immunosup-
pressive therapy is indicated when there is evidence of
disease progression and/or when organ dysfunction is pre-
sent [1]. A Cochrane review investigating the role of
immunosuppressive therapy in sarcoidosis reported that
there is a paucity of studies on the role of steroid-sparing
immunosuppressive agents in sarcoidosis [2]. Corticoste-
roids are generally the first line therapy in sarcoidosis and
are often effective in the short term management of pul-
monary sarcoidosis. In addition, there is little evidence that
corticosteroids modify long term disease progression [3,4]
and they are fraught with numerous and debilitating side
effects [5].
Steroid sparing agents are used in sarcoidosis patients who
require long term therapy to control their disease and to
minimize the side effects and complications of corticosteroid
therapy [6]. Methotrexate is the most commonly chosen
steroid-sparing drug in sarcoidosis [7], with an estimated ef-
ficacy of about 47% for improvement in lung disease [8]. Pa-
tients occasionally do not tolerate methotrexate due to
various side effects [8]. Two case series suggested a beneficial
effect for leflunomide, another steroid-sparing agent, in
sarcoidosis [9,10]. Azathioprine is less commonly used in the
management of sarcoidosis [7]. A retrospective study that
compared outcomes between patients treated with metho-
trexate versus azathioprine showed similar physiological re-
sponses but a higher risk of infection with azathioprine [11].
Biological agents, specifically anti-tumor necrosis alpha (TNF-
a) agents, are considered third line therapeutic agents to
manage sarcoidosis after patients have failed first and second
line agents [6].
There is only one small study of n Z 10 subjects pub-
lished evaluating the efficacy of mycophenolate mofetil
(MMF) in sarcoidosis, suggesting that MMF might be used as
a steroid-sparing agent [12]. Based on other studies, MMF
appears to be a safe and effective treatment for connective
tissue disease associated interstitial lung diseases (CTD-ILD)and is becoming first line therapy for these diseases
[13,14]. As a result of this experience, our clinical
sarcoidosis group has used MMF an alternative steroid
sparing agent in sarcoidosis patients who are intolerant to
or have failed to respond to methotrexate or other immu-
nosuppressive agents. The goal of our study was to retro-
spectively evaluate the efficacy of MMF in the management
of sarcoidosis patients failing or intolerant to their previous
immunosuppressive regimen.Methods
Utilizing a retrospective chart review method, all sarcoid-
osis patients who were prescribed MMF between January
2008 and October 2011 were identified through a search of
the ICD-9 codes for sarcoidosis using the National Jewish
Health (NJH) electronic medical record database and our
sarcoidosis research database. Subjects had to meet the
American Thoracic Society (ATS)/European Respiratory So-
ciety (ERS) diagnostic criteria for sarcoidosis [1] requiring
biopsy confirmation of granulomatous inflammation and
exclusion of other potential causes of sarcoidosis; cases of
Lofgren’s were an exception as diagnosis is based on clinical
criteria. In addition, all cases were required to have been
treated with MMF therapy for a minimum of 6 months and
previously with another steroid sparing immunosuppressive
agent with or without corticosteroids for a minimum of six
months. MMF was started at the discretion of the treating
physician and not based on specific protocols or criteria.
Those subjects who were started on another immunosup-
pressive therapy, including prednisone, at the time that
MMF was initiated or whose dose of another immunosup-
pressant was escalated at the time that MMF was started
were excluded from this study. Subjects were also excluded
if they were on MMF therapy for less than 6 months or
lacked medical record documentation of treatment for at
least 6 months.
Once subjects met the above inclusion and exclusion
criteria, the following data was extracted from the medical
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and smoking status); corticosteroid dose at MMF initiation,
3 and 6 months after MMF initiation; immunosuppressive
(IS) regimen from six months before and up to the time MMF
was administered; indication for initiation of MMF,
including target organ(s) that necessitated treatment with
MMF; duration of disease; organ involvement based on the
assessment of the treating physician; and side effects
attributed to the immunosuppressive therapy. In addition,
physiologic data was abstracted including pulmonary func-
tion test (PFT) data (forced expiratory volume in the first
second (FEV1), forced vital capacity (FVC), ratio of forced
expiratory volume in the first second (FEV1)/forced vital
capacity (FEV1/FVC), total lung capacity (TLC), diffusion
capacity for carbon monoxide (DLCO), and diffusion ca-
pacity for carbon monoxide adjusted for alveolar volume
(DLCO/VA) absolute values) at 12 and 6 months pre and post
therapy with MMF and at time of MMF initiation, allowing a
one month window for obtaining lung function data. All
PFTs were performed according to ATS standard criteria
[15]. The side effect profile of MMF in the study population
was extracted from the clinic notes. This protocol was
approved by the NJH Institutional Review Board. Informed
consent was waivered due to the retrospective nature of
the study.Statistical analysis
The effect of MMF on lung function was the primary
outcome of this study, and was assessed by comparing the
changes in FVC and DLCO from pre MMF treatment to the
most recent post MMF treatment. We focused our analysis
on FVC and DLCO as these two measurements are
frequently used to assess functionally important pulmonary
changes in sarcoidosis [16]. A paired t-test was used to
assess the mean changes in FVC and DLCO pre and post MMF
therapy. Wilcoxon matched pairs signed rank tests were
used to compare changes in corticosteroid dose from MMF
start to 6 months and to 12 months post MMF start.
In addition, as we had longitudinal data for analysis,
linear mixed models (LMMs) were used to account for the
longitudinal nature of this study. The outcomes of interest
were the following PFT parameters: FEV1, FVC, FEV1/FVC,
TLC, DLCO, and DLCO/VA using absolute values. The pre-
dictors of interest were visit (12 months pre-MMF therapy
(2), 6 months pre-MMF therapy (1), MMF start (0), 6
months post-MMF therapy (1) and 12 months post-MMF
therapy (2)), group (methotrexate intolerance due to side
effects vs. treatment failure based on the assessment of
the treating physician), and the interaction between visit
and group. Also included in the model was a spline term at
the time of MMF administration (visit Z 0), and an inter-
action between the spline term and group. The spline term
allowed the slope before and after the time of MMF
administration to differ. Visit was treated as a continuous
variable in order to include the spline term in the model.
The following covariates were included in all models: age,
gender, race (Caucasian, Not Caucasian), smoking (former,
never), and indication for IS therapy (lung, other organ
system involvement with sarcoidosis). In order to account
for repeated measures in this study, different covariancestructures were considered, such as Compound Symmetric
(CS) and First-order Autoregressive (AR-1), and the covari-
ance structure that led to the best model fit was chosen. As
such, all the LMMs contained the CS covariance matrix.
Random intercepts were included in all models where
possible (some models did not converge on a solution with




We identified a total of 76 sarcoidosis patients who were
prescribed MMF between January 2008 and October 2011 at
NJH. Of these, 39 patients were excluded from analysis; of
these 19 had another immunosuppressive (IS) agent started
at the same time MMF was started, six did not tolerate MMF
and stopped it within one month and 14 had inadequate PFT
data for analysis. The final population used in this study
consisted of 37 sarcoidosis patients (Table 1). The main
difference between the cohorts was the baseline immuno-
suppressive therapy, as the subjects who were excluded
were more likely to be on no therapy prior to starting MMF
(23.1% vs 0.05%) and to be started on MMF and prednisone
simultaneously as initial therapy.
The study cohort (n Z 37) was predominantly male,
Caucasian and never smokers. Pulmonary involvement was
the main indication for IS therapy (75.7% for the study
cohort, 71.4% in the treatment failure group and 81.3% in
the treatment intolerant group). The treating physician’s
assessment of lack of efficacy of the previous IS regimen
was the main reason patients were started on MMF (56.8%).
There was no difference in the mean duration of disease
from time of initial diagnosis to time of MMF treatment
between the intolerant group and the treatment failure
group (mean 69.63  66.43 vs 53.25  31.99months
respectively, p Z 0.33). The majority of patients were on
combined therapy; 75.7% of patients were on prednisone,
70.3% were on methotrexate initially, two patients were on
hydroxychloroquine, and one patient was on azathioprine.
The average MMF dose used was 2236 mg in twice-daily
divided doses (32.4% were on 3000 mg daily, 59.5% were
on 2000 mg daily, and 8.1% were on 1500 mg or less daily).
MMF may impact lung function in those intolerant
to methotrexate
We initially compared the difference in mean change in
absolute values of FVC and DLCO at 6 months before and
after starting MMF therapy and at 12 months before and
after starting MMF therapy. There were no statistically
significant changes in absolute FVC and/or DLCO at either
time point. However, change in DLCO 12 months after
starting MMF therapy compared to 12 months before
starting MMF therapy showed a trend towards an increase in
the entire cohort (p Z 0.07) (Table 2).
We subsequently divided and analyzed the cohort by
subgroups. First, we divided the cohort based on the organ
system indication for IS therapy (pulmonary vs non-
pulmonary indication for therapy). We also divided the
Table 1 Study population characteristics.
Eligible study cohort n Z 37 Ineligible study cohort n Z 39 P value
Age, years SD 54  11 53  12 (amissing data n Z 4) ns
Male % 56.8 56.4 ns
Race %
- Caucasian 73.0 69.2 ns
- African American 21.6 18
- Other 5.4 12.8
Smokers % (A/F/N) 0/32.4/67.6 0/25.6/74.4 ns
Pre-MMF immunosuppressive
therapya % (n)
Prednisone 75.7 (28) Prednisone 61.5 (24) <0.05
Methotrexate 70.3 (26) Methotrexate 33.3 (13)
No therapy 0.05 (2) No therapy 23.1 (9)
Hydroxychloroquine 0.05 (2) Hydroxychloroquine 0.05 (2)
Azathioprine 0.03 (1) Leflunomide 0.03 (1)
Abbreviations: ns: not significant, SD: standard deviation, A/F/N: active/former/never, N/A: not applicable, IS: immunosuppressive,
MMF: mycophenolate mofetil.
a Most patients were on combination therapy.
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therapy (perceived lack of efficacy of baseline therapy by
the treating physician vs intolerance to baseline therapy).
For both of these analyses, we found no statistically sig-
nificant change in the change in the mean FVC and DLCO
before and after MMF therapy between any of the two time
points (Table 2).
We then analyzed the data using a linear mixed models
approach to account for the longitudinal nature of the
study. The effects of MMF on changes in PFT were consis-
tent for the absolute value of FEV1, FVC, DLCO and DLCO/
VA, where baseline therapy intolerant subjects showed a
trend towards improvement in PFT measurements after
starting MMF (Fig. 1, Table 1S). In contrast, the baseline
treatment failure patients continued to show a decline in
PFT measurements even after starting MMF (Fig. 1, Table
1S).Table 2 Changes in pulmonary physiology before and after the
Cohort FVC (L)
D pre-MMF, D post-MMF
Diff (SD), p value
6 months 12
Entire cohort 0.047, 0.118 0
0.071 (0.53), 0.47 0
n Z 29 n Z
Pulmonary indication for is therapy 0.07, 0.10 0
0.02 (0.52), 0.86 0.0
n Z 19 n Z
Treatment failure 0.01, 0.18 0
0.19 (0.52), 0.28 0
n Z 17 n Z
Intolerance to current therapy 0.15, 0.02 0
0.12 (0.49), 0.43 0.1
n Z 11 n Z
Abbreviations: MMF: mycophonelate mofetil, D pre-MMF: change in va
MMF: change in value from starting MMF to time point after startingMMF is effective as a steroid sparing agent
We had available data from 32 patients regarding cortico-
steroid (CS) dosing. 11/32 (34%) patients were not on CS at
the time MMF was started and 21 were on at least 5 mg or
higher (mean dose 14.2  12.4; range 5e60 mg). After 6
months and 12 months of MMF therapy, the mean CS dose
was 8.6 (9.6) mg and 8.9 (8.1) mg with a statistically
significant decline in dose noted between the MMF start and
6 month follow up (pZ 0.004). Of note, 16/21 (76.2%) were
on a prednisone dose of 5 mg per day or higher at MMF start
and 6/16 (37.5%) and 4/16 (25%) were on a prednisone of
5 mg per day or higher at 6 and 12 months respectively. In
addition, 5/21 (23.8%) and 8/21 (38.1%) subjects were able
to discontinue prednisone after 6 and 12 months of therapy
with MMF. This suggests that treating physicians are likelyrapy with MMF.
DLCO (L)
D pre-MMF, D post-MMF
Diff (SD), p value
months 6 months 12 months
.057, 0.015 0.30, 0.02 L1.65, 0.08
.042 (0.45), 0.62 0.32 (3.15), 0.72 1.74 (3.33), 0.07
29 n Z 13 n [ 14
.10, 0.04 0.39, 0.15 1.60, 0.21
7 (0.51), 0.59 0.24 (2.97), 0.79 1.39 (3.23), 0.21
18 n Z 11 n Z 10
.02, 0.04 0.02, 0.63 1.51, 0.41
.02 (0.34), 0.84 0.61 (3.28), 0.61 1.1 (3.34), 0.35
18 n Z 8 n Z 9
.12, 0.02 0.75, 1.06 1.92, 0.96
4 (0.6), 0.47 1.82 (2.54), 0.18 2.87 (3.35), 0.13
11 n Z 5 n Z 5
lue from time point before starting MMF to start of MMF, D post-
MMF, Diff: difference, SD: standard deviation.
Figure 1 FVC and DLCO by group, spline at visit Z 0. Plotted values are estimates obtained from linear mixed models. Results
apply to no prior smoking Caucasian male subjects of average age 54 years with active or progressive pulmonary sarcoidosis as the
indication for IS therapy.
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who have been treated with MMF.
MMF is tolerated by the majority
Of all of the subjects treated with MMF, 6/76 (8%) could not
tolerate MMF and stopped the drug within 1e2 months of
starting it. Two patients complained of headaches, one of
fatigue, one developed pneumonia and refused to continue
MMF, and the reason for stopping MMF for 2 patients was not
specified in their medical records. For patients who
remained on therapy with MMF (n Z 37), four developed
upper respiratory tract infections, two had urinary tract
infections, one developed leukopenia, one thrombocyto-
penia, one cold sores, one skin sores and one gastrointes-
tinal symptoms (nausea, loose stools and diarrhea) yielding
a total side effect rate of 16/76 (21.1%).
Effect of MMF on extra-pulmonary sarcoidosis
A number of our patients had non-pulmonary involvement
in addition to pulmonary involvement, as follows: 10/37
patients had cardiac involvement, 5/37 hypercalcuria, 4/37
hepatic, 3/37 ophthalmic and 2/37 cutaneous. Unfortu-
nately, 3/10 of the cardiac sarcoidosis patients had inade-
quate clinical data to assess impact of MMF on cardiac
sarcoidosis, while 6/7 of the remaining cardiac sarcoidosis
subjects with available clinical data had a cardiac 18-fluo-
rodeoxy-glucose positron emission test (cFDG-PET) prior to
initiation of MMF. All 6 of these patients showed either a
patchy or patchy on diffuse pattern of uptake in the
myocardium. At 6 months, all had repeat cFDG-PET and
demonstrated improvement or resolution of their myocar-
dial hypermetabolic activity. Furthermore, 7/10 cardiac
patients had echocardiograms prior to initiation of MMF,
with 4/7 demonstrating normal left ventricular (LV) func-
tion that was unchanged on follow up testing. Two had
moderate reduction in LV function (ejection fraction 35%)
and one demonstrated slight improvement in LV ejection
fraction from 34% to 40e45% and the other showed nochange, while the last patient had a slightly reduced LV
function (EF 45e50%) that normalized after 6 months of
therapy. Because of the small numbers of other organ
involvement, we were unable to assess the response in
treatment with MMF.Discussion
There are currently no Food and Drug Administration (FDA)
approved steroid sparing agents for the management of
sarcoidosis. Corticosteroids have been considered first line
therapy for active sarcoidosis, but are fraught with side
effects [5]. While methotrexate is the most commonly use
steroid sparing agent used in sarcoidosis, other therapies
including leflunomide, azathioprine and mycophenolate
mofetil (MMF) used as second line therapies for sarcoidosis
[7] have not been studied in randomized controlled trials
and have only been evaluated in a few clinical studies
except for one small study evaluating methotrexate as a
steroid sparing agent in acute sarcoidosis [17]. We retro-
spectively investigated the efficacy of MMF in sarcoidosis,
focusing on the use of MMF to treat pulmonary involvement.
Our findings suggest that MMF may not offer an additional
advantage in pulmonary sarcoidosis patients who have
failed other steroid-sparing agents (with or without corti-
costeroid therapy). However, in subjects who are intolerant
to other IS, MMF may result in some improvement in lung
function. In addition, we found that MMF may be useful in
enabling a reduction in prednisone dose. For the majority
of treated sarcoidosis patients, MMF was well tolerated.
Thus, MMF appears to have potential as a second line agent
for some pulmonary sarcoidosis subjects. However, its use
as the initial steroid-sparing agent in pulmonary sarcoidosis
as a second line agent will require additional investigation.
Methotrexate remains the preferred choice as a steroid
sparing agent amongst sarcoidosis experts [7] but due to
intolerance or lack of efficacy of methotrexate by some
patients, investigators have looked at the role of other
steroid sparing agents in sarcoidosis [9e12,18]. Lower et al.
reported a 10e15% improvement in FVC after 6 months of
1668 N. Hamzeh et al.therapy with methotrexate in 12% of their cohort whereas
in our cohort 9% showed at least a 10% improvement in their
FVC after 6 months [19]. Sahoo et al. investigated the po-
tential role of leflunomide in pulmonary sarcoidosis [9] and
showed a statistically significant (190 ml) absolute change
in FVC from 6 months prior to initiating leflunomide to 6
month post leflunomide therapy [9]. Vorselaars et al. also
reported a statistically significant (97 ml) absolute change
in vital capacity between one year before and after therapy
with methotrexate or azathioprine [11]. Our findings with
MMF in the group intolerant to their current IS therapy
showed a 120 ml absolute improvement in FVC from 6
months prior to MMF to 6 months post MMF therapy and a
140 ml absolute improvement in FVC from 12 months prior
to MMF to 12 months post MMF therapy. However, we did
not show a statistically significant change, possibly due to
lack of power with small numbers. In a recent report on the
use of MMF in 10 patients with chronic pulmonary sarcoid-
osis, Brill et al. demonstrated the ability of MMF to maintain
lung function while reducing the dose of corticosteroids
[12]. However, in this study MMF was not used as a third line
agent. This study and ours support the potential role of MMF
as a steroid-sparing agent in sarcoidosis while maintaining
or possibly improving lung function.
Our study also demonstrates the potential role of MMF as
a steroid-reducing agent in sarcoidosis. 76.2% of our cohort
was on prednisone at a dose of 5 mg or higher at the time
MMF was initiated and only 37.5% and 25% were on 5 mg a
day or higher at 6 and 12 months respectively. Vorselaars
et al. showed a mean decrease of daily prednisone dose of
6.32 mg over 1 year [11] with methotrexate or azathioprine
therapy, while our cohort demonstrated a similar 5.9 mg
decrease in prednisone dose over one year. Sahoo et al.
reported that 31/41 (31.7%) of their cohort was able to
wean off prednisone entirely after 6 months of therapy [9]
while in our cohort 23.8% and 38.1% of patients were able to
wean off CS after 6 and 12 months of therapy respectively.
In addition, MMF overall was well tolerated. Specifically, we
found that the overall side effect rate of MMF in our entire
cohort of 76 subjects was 21.1%. This rate is lower than that
reported for azathioprine (34.6%) [11] and leflunomide
(34%) [9] but similar to that reported for methotrexate
(18.1%) [11].
A retrospective study such as this is subject to several
limitations including the lack of a systematic method for
collecting the data, lack of standardization of indications
for therapy, dosing regimens and management of concom-
itant therapies and a control or placebo group. We
excluded patients who were started on corticosteroids or
had their corticosteroid dose increased at the time of
initiating MMF to avoid attributing any potential improve-
ment from corticosteroid therapy to the use of MMF. Our
cohort had two main indications for initiation of MMF: lack
of perceived benefit by the treating physician or develop-
ment of side effects on the current IS regimen. We analyzed
both subgroups separately and found no statistically sig-
nificant differences in FVC or DLCO in either subgroup.
However, the methotrexate intolerant group tended to
show a positive increase in FVC and DLCO at the 12 month
follow-up, whereas the treatment failure cohort tended to
show a persistent decline in FVC and DLCO at 12 months
after initiation of MMF. The relatively small cohort sizeprobably limited our power to detect a true difference in
the sub-group analyses. These limitations may explain why
we failed to find an effect of MMF in sarcoidosis, in contrast
to the CTD-ILDs or it may be that MMF is not as an effective
treatment once individuals with sarcoidosis have failed
other IS.
In summary, our study does not show a significant benefit
from MMF in patients already failing another second line
agent but a trend towards improvement in DLCO in those
intolerant to methotrexate. This may suggest a potential
role of MMF in a selected group of patients but these find-
ings will need to be confirmed and validated in a prospec-
tive study. Our study does suggest that MMF is effective as a
steroid-sparing agent in sarcoidosis, as our subjects on MMF
were able to reduce or wean off corticosteroids. Finally,
our study did not address whether MMF is useful as a first-
line steroid sparing agent in the management of pulmonary
sarcoidosis; this will need to be addressed by larger ran-
domized controlled clinical trials.Conflict of interest
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